Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025

Published: 2025-05-15 07:51:00 ET GALT

Published on 05/15/2025 at 07:51, updated on 05/15/2025 at 09:21

Galectin Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2025. For the first quarter, the company reported net loss was USD 9.63 million compared to USD 11.49 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.19 a year ago.

Diluted loss per share from continuing operations was USD 0.15 compared to USD 0.19 a year ago.